...
首页> 外文期刊>Oncology reports >Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer.
【24h】

Concurrent chemoradiotherapy for organ function preservation in advanced patients with hypopharyngeal and laryngeal cancer.

机译:下咽癌和喉癌晚期患者的同步放化疗可以保持器官功能。

获取原文
获取原文并翻译 | 示例

摘要

Preservation of the larynx is the most critical factor influencing quality of life in the treatment of head and neck cancer. This clinical study focuses on laryngeal function-preserving chemoradiotherapy for locally advanced hypopharyngeal and laryngeal cancer. Thirty-two resectable cases with histologically proven squamous cell carcinoma undergoing function-preserving therapy were examined. Induction chemotherapy comprised cisplatin and 5-fluorouracil, and another cycle of chemotherapy was performed for responders. Chemoradiotherapy comprised conventional irradiation and weekly chemotherapy (nedaplatin plus docetaxel). Non-responder patients were excluded from further chemotherapy and were changed to other surgical treatment. Three patients were non-responders for induction chemotherapy, and 29 patients were treated with chemoradiotherapy. Thus, 21 out of 29 patients obtained preserved laryngeal function. Initial larynx preservation rate with these treatment strategies was 93.8%. This study provides a new concept for laryngeal function-preserving treatment that should be considered for locally advanced laryngeal and hypopharyngeal cancer.
机译:喉头的保存是影响头颈癌患者生活质量的最关键因素。这项临床研究专注于针对局部晚期咽喉癌和喉癌的保留喉功能的放化疗。检查了32例可切除的组织学证实为鳞状细胞癌的保留功能患者。诱导化疗包括顺铂和5-氟尿嘧啶,并对应答者进行了另一轮化疗。放化疗包括常规放疗和每周化疗(奈达铂加多西他赛)。无反应的患者被排除在进一步的化疗之外,而改为其他手术治疗。 3例对诱导化疗无反应,29例接受放化疗。因此,29例患者中有21例保留了喉功能。这些治疗策略的最初喉部保存率为93.8%。这项研究为保留喉功能的治疗提供了一个新概念,对于局部晚期喉癌和下咽癌,应考虑采用这种方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号